TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
Recruiting
N/A
Interventional Study
Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Glioblastoma Multiforme, Adult
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 92 (estimated)
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastom…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years
* Karnofsky Performance Status ≥70
* Histologically confirmed IDH-wildtype glioblastoma
* First, second, or third recurrence
* Radiological recurrence according to RANO 2.0 criteria
* Prior radiotherapy and temozolomide treatment
* At least 6 months since complet…
Contacts